The Effect of Inflammation & Damage to Lymph Node Structures on Durable

Status Active, not recruiting

Clinical Trial Summary

Hypothesis: Infections other than HIV can cause LN inflammation and collagen damage to the fibroblastic reticular cell network (FRCn), which will lead to CD4 T cell depletion and impaired vaccine responses. This protocol will study yellow fever vaccine (YFV) in two cohorts of people, one from Uganda and the other from Minnesota where we collect lymphoid tissues (LT) and peripheral blood monocytes (PBMCs) before and after vaccination using a new technique to catalog infectious burden of the individual, determine the relationship between IA, Infections, and immune response.

Clinical Trial Description

The primary aim of this study is to determine the difference between antibody titers in the two study groups and study the relationship between endemic infections, IA, the FRCn, and CD4 and CD8 T cell subsets and the magnitude and durability of neutralizing antibody response to YFV in a cohort shown to have elevated IA, a damaged FRCn, and pan T cell depletion and a cohort that does not. This is a single arm, open-label, two cohort study of healthy adults in Kampala, Uganda and in Minnesota, USA. The cohort in Uganda will be 30 adults (15 men and 15 women) and the cohort in Minnesota will be 16 adults (8 men and 8 women). Everyone will be screened to ensure there are no contraindications to receiving YFV (e.g., immunosuppression) or the planned procedures. The inclusion and exclusion criteria are discussed in detail in the protocol that is included in the appendix. Participants will have an inguinal lymph node and adjacent adipose tissue biopsy and leukapheresis prior to YFV and again 3 weeks after the vaccine administration. The vaccine will be given in the contralateral thigh from the first LN biopsy so that the second biopsy will be from a draining LN. PBMC and plasma as well as urine and stool will be collected at regular intervals over the 18-month follow-up period and leukapheresis will be done again at the month 18 visit. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04269265
Study type	Interventional
Source	University of Minnesota
Contact
Status	Active, not recruiting
Phase	Phase 1/Phase 2
Start date	July 1, 2020
Completion date	June 30, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01436396` - Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers	Phase 3
Recruiting	`NCT05568953` - An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity	Phase 2
Recruiting	`NCT05447377` - A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL® In Healthy Infants	Phase 3
Active, not recruiting	`NCT05011123` - Study on an Investigational Yellow Fever Vaccine Compared With Stamaril in Adults in Europe and Asia	Phase 2
Completed	`NCT04267809` - Modulate Cellular Stress in the Immune Cells to Reduce Rate of Symptomatic Viral Infection	Phase 2
Completed	`NCT01943305` - The Role of Pre-existing Cross-reactive Antibodies in Determining the Efficacy of Vaccination in Humans	Phase 2
Completed	`NCT02991495` - Immunogenicity and Safety of Fractional Doses of Yellow Fever Vaccines (YEFE)	Phase 4
Not yet recruiting	`NCT03725618` - Immunogenicity of Fractional One-fifth and One-half Doses of Yellow Fever Vaccine Compared to Full Dose in Children 9-23 Months Old	Phase 4
Completed	`NCT01466387` - A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults	Phase 3
Completed	`NCT04059471` - Non- Inferiority Fractional-doses Trial for Yellow Fever Vaccine	Phase 4
Completed	`NCT02572518` - Immunity After Two Doses of Yellow Fever Vaccine	N/A
Recruiting	`NCT00694655` - Human Immune Responses to Yellow Fever Vaccination	Phase 4
Not yet recruiting	`NCT05332197` - Booster Vaccine for Yellow Fever	Phase 3
Recruiting	`NCT05421611` - A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL	Phase 3
Completed	`NCT03116802` - Yellow Fever Vaccine on Statin/ Non Statin Subjects	Phase 2
Completed	`NCT02743455` - A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers	Phase 1
Completed	`NCT01426243` - The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient.	Phase 3
Completed	`NCT00982137` - Study of Live Attenuated Japanese Encephalitis Vaccine (ChimeriVax™-JE) and Yellow Fever Vaccine (STAMARIL®)	Phase 2
Completed	`NCT03870061` - Evaluation of an Infant Immunization Encouragement Program in Nigeria	N/A
Completed	`NCT00995865` - Trial of Yellow Fever Inactivated Vaccine	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

The Effect of Inflammation and Damage to Lymph Node Structures on Durable Protective Immunity Following Yellow Fever Vaccination

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms